Status:
COMPLETED
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
Lead Sponsor:
Silkiss Eye Surgery
Collaborating Sponsors:
Benign Essential Blepharospasm Research Foundation
GW Pharmaceuticals Ltd
Conditions:
Blepharospasm
Blepharospasm, Benign Essential
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a fo...
Eligibility Criteria
Inclusion
- Patients in the private practice of the principal investigator with an ICD code of "blepharospasm" and:
- undergoing routine maximal botulinum therapy
- experiencing break through symptoms of spasm
- marijuana naïve
Exclusion
- concomitant diagnosis of epilepsy
- patients whom are not marijuana naive
- patients on concurrent anti-epileptics
- patients who are pregnant or wishing to become pregnant
- patients not wishing to participate in the study.
Key Trial Info
Start Date :
May 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04423341
Start Date
May 20 2020
End Date
October 1 2021
Last Update
November 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Silkiss Eye Surgery
Oakland, California, United States, 94609